56 Results Sort by:
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers. Key Benefits A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers. The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 3/1/2024       Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
ONC201 for the Treatment of Vascular Aneurysms
Application A repurposed therapeutic for the preventative and treatment of aneurysms. Key Benefits A repurposed cancer drug that targets cells known to be damaged during the progression of an aneurysm. The drug has been tested within an animal model of aortic aneurysms, where it prevented the severe complications of the disease and protected the...
Published: 3/1/2024       Contributor(s): Alejandra Maria San Martin
Small Molecules for Treating Cystic Fibrosis
ApplicationSmall molecule compounds to potentiate most common type of CFTR mutation in cystic fibrosis patients.Key BenefitsPotentiates ΔF508-hCFTR mutation, addressing more than 60 percent of CF patients. Market SummaryCystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and ion channel that malfunctions in the genetic...
Published: 7/28/2023       Contributor(s): Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
Microfluidic and Organotypic Tumor Slice Culture Drug Testing Platform for Individualized Cancer Therapy
Application A drug combination screening/testing platform for individualized cancer therapy. Key Benefits Rapid screening of effective drug combination. Integrated tumor microenvironment. Identifying personalized therapy for individual cancer patient. Market Summary Traditional two-dimensional (2D) in vitro culture models for drug development...
Published: 1/25/2024       Contributor(s): Tobey John MacDonald, Anna Kenney, Abhinav Dey, YongTae (Tony) Kim
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application Therapeutic use of miR-483 mimic for treating aortic valve clarification. Key Benefits MiR-483 or mimics of miR-483 could be used as a therapeutic. Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification. Market Summary Aortic stenosis (AS) is the most common type of heart...
Published: 3/1/2024       Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform
­ Application High Throughput Screening for identifying effective immuno-modulators. Key Benefits HT screening platform replicating complex immune medicated response to facilitate discovery of small molecule immunomodulatory agents. Simplicity and dual readouts of the design enable the screening of large chemical libraries to identify compounds...
Published: 12/1/2023       Contributor(s): Xiulei Mo, Haian Fu
Multifunctional Drug and Immune Modulator Delivery Nanoparticles for the Treatment of Cancer Patients with Comorbid Atherosclerosis
Application A multifunctional immuno-therapy nanoparticle (PD1Y-HANP/Avasimbe) that has ability of targeting and inhibiting immune checkpoint PDL-1 while producing therapeutic effects on tumors and atherosclerosis. Key Benefits Multifunctional immunotherapy for cancer patients with atherosclerosis. Shown to inhibit tumor growth and prevention...
Published: 1/10/2024       Contributor(s): Lily Yang, Lei Zhu
Mitigation of Negative Effects of Melphalan on Cardiomyocytes with N-acetyl-L-cysteine (NAC) Treatment
­ Application NAC (N-acetyl-L-cystine) as an antioxidant to reduce chemotherapy induced oxidative stress and cardiotoxicity. Key Benefits Mitigates cardiotoxic side effects of alkylating agent, melphalan in human cardiomyocytes. Market Summary Melphalan is a chemotherapeutic commonly used to treat various cancers including multiple myeloma,...
Published: 11/27/2023       Contributor(s): Chunhui Xu, Anant Mandawat, Rui Liu
Small Molecule Compound to Treat Neurological Diseases
Application NMDAR agents for the treatment of various neurological diseases. Key Benefits Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs. The compound has excellent Lipinski drug-like properties including low molecular weight and cLogP, as well as water solubility. The initial studies have determined...
Published: 9/5/2023       Contributor(s): Dennis Liotta, Stephen Traynelis, Hongjie Yuan, Matthew Epplin, Samantha Summer, David Menaldino, Leon Jacobs, Adam McCallum
SARS-CoV-2 Subgenomic Replicon (SARS2-Rn)
Application A series of SARS-CoV-2 sub-genomic replicons as artificial bacterial chromosomes for the screening of SARS-CoV-2 in studies such as drug discovery and inhibitors assay. Key Benefits Can be used at a lower biosafety level than non-artificial copies of SARS-CoV-2. Can be used for high throughput screening and characterization of SARS-CoV-2...
Published: 1/10/2024       Contributor(s): Stefan Sarafianos, Shuiyun Lan
1 2 3 4 5 6